Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2003 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Arthritis Foundation
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00008749
First received: January 16, 2001
Last updated: June 23, 2005
Last verified: December 2003
  Purpose

Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.


Condition
Lupus Erythematosus, Systemic

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

Resource links provided by NLM:


Further study details as provided by National Center for Research Resources (NCRR):

  Eligibility

Ages Eligible for Study:   13 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion:

A diagnosis of systemic lupus erythematosus

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00008749

Contacts
Contact: Randy Q Cron, MD, Ph.D. 215-590-1844

Locations
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104-4318
Contact: Randy Q Cron, M.D., Ph.D.    215-590-1844      
Sponsors and Collaborators
Arthritis Foundation
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00008749     History of Changes
Other Study ID Numbers: NCRR-M01RR00240-1736
Study First Received: January 16, 2001
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on April 16, 2014